Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Testicular cancer incidence predictions in Europe 2010–2035: A rising burden despite population ageing

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Menstrual pain and risk of epithelial ovarian cancer: Results from the Ovarian Cancer Association Consortium

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Tibolone and risk of gynecological hormone sensitive cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Does HPV status influence survival after vulvar cancer?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Triage May Improve Selection to Colonoscopy and Reduce the Number of Unnecessary Colonoscopies

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The current epidemic of HPV-associated oropharyngeal cancer: An 18-year Danish population-based study with 2,169 patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
YKL-40 is a glycoprotein secreted by macrophages, neutrophils and malignant tumor cells. Elevated serum levels of YKL-40 are associated with poor prognosis in several malignancies. In this study, we examined the prognostic value of serum YKL-40 before treatment and during follow-up in patients with squamous cell carcinoma of the head and neck (HNSCC). YKL-40 was determined by ELISA retrospectively in serum from 173 patients with primary HNSCC before treatment and up to 2 years after treatment. Median follow-up time was 7.9 years. YKL-40 protein expression in tumor biopsies was assessed by immunohistochemistry in 50 patients. Pretreatment serum YKL-40 was elevated in 53%. Patients with high serum YKL-40 had shorter survival than patients with normal serum YKL-40 (33 vs. 84 months; p = 0.008). Multivariate Cox analysis including pretreatment serum YKL-40, age, sex, primary tumor site, TNM classification and treatment demonstrated that TNM classification (HR = 2.61, p = 0.02) and serum YKL-40 (log-transformed continuous variable: HR = 1.55, p
OriginalsprogEngelsk
TidsskriftInternational journal of cancer. Journal international du cancer
Vol/bind122
Udgave nummer4
Sider (fra-til)857-63
Antal sider7
ISSN0020-7136
DOI
StatusUdgivet - 15 feb. 2008

ID: 42998747